Mucothiol

Quick links to important sections

Mucothiol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucothiol

What is Mucothiol?

Mucothiol is a pharmacological agent classified as a mucolytic. It is primarily used to manage respiratory conditions characterized by the production of excessive or thick, viscous mucus. By altering the physical properties of these secretions, the medication facilitates their clearance from the respiratory tract.

Composition and Mechanism

The active ingredient in Mucothiol is carbocisteine. Unlike some other treatments that break down mucus after it has already been formed, carbocisteine works during the production phase within the mucus-secreting cells.

It acts on the enzymes responsible for synthesizing the building blocks of mucus. Specifically, it promotes the production of sialomucins and reduces the production of fucomucins. Sialomucins are less viscous and more fluid, which helps restore the natural balance of the airway secretions. This process results in mucus that is thinner and easier to expel through coughing or natural ciliary action.

Clinical Applications

Mucothiol is utilized in various chronic and acute respiratory disorders where mucus obstruction is a concern. These include:

  • Chronic Obstructive Pulmonary Disease (COPD): Helping to reduce the frequency of exacerbations by maintaining clearer airways.
  • Chronic Bronchitis: Assisting in the management of long-term inflammation and secretion buildup.
  • Acute Respiratory Infections: Providing symptomatic relief in cases of influenza, colds, or acute bronchitis where phlegm is difficult to clear.
  • Otolaryngological Conditions: Sometimes used in the management of glue ear (otitis media with effusion) to reduce the viscosity of fluid in the middle ear.

Role in Respiratory Health

The primary goal of using Mucothiol is to improve airflow and reduce the physical effort required to clear the throat and lungs. By improving the fluidity of the mucus, it helps protect the delicate lining of the respiratory tract and may reduce the likelihood of secondary bacterial infections that can occur when stagnant mucus remains trapped in the airways.

What side effects are possible with Mucothiol?

Possible side effects and safety information

The regulatory safety profile of Mucothiol (Dacisteine) is defined by official government health authorities to ensure a standardized presentation of documented risks. The primary method for communicating possible adverse reactions involves classifying them by both frequency and the affected System-Organ-Class (SOC).

Adverse Reaction Classification

Official regulatory documents categorize adverse reactions into frequency tiers—such as Very Common, Common, Uncommon, Rare, and Very Rare—to communicate their relative occurrence based on clinical data. These reactions are then grouped into System-Organ-Classes, which helps to map potential effects to specific body systems, such as the gastrointestinal or nervous systems, as defined by regulatory standards.

Documented Safety Constraints

The safety profile also includes specific regulatory statements regarding clinically significant reactions, often termed Serious Adverse Reactions. These reactions require immediate attention and are explicitly documented in official prescribing information.

Furthermore, regulatory documents outline Population-Specific Safety Considerations. These official statements address whether particular patient groups, such as older adults or those with existing hepatic (liver) or renal (kidney) impairment, have different safety profiles or require specific cautionary context. Safety-related restrictions and limitations are also included when formally required by the regulating body, ensuring that the medicine’s risk profile is communicated neutrally, without providing clinical advice or therapeutic claims. The full safety structure is designed to provide a comprehensive, standardized summary of documented risks.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for a potential overdose of Mucothiol (Dacisteine) is established by mandating immediate emergency action, as specific drug-related overdose data is not publicly detailed in government prescribing information.

Documented Manifestations and Serious Outcomes

No specific clinical signs, symptoms, or physiological effects associated with a Dacisteine overdose are formally documented in official regulatory labeling (e.g., FDA or EMA documents). Consequently, no unique severe or life-threatening outcomes are officially cataloged for this product.

Required Emergency Action

If a suspected overdose occurs, or if ingestion exceeds the amount stated on the official label, immediate medical attention must be sought without delay. This is a standard and universally mandated requirement in medical product safety documentation to ensure professional clinical assessment and intervention.

Management and Antidote Information

Official regulatory guidance confirms that no specific antidote is known for Dacisteine overdose. Therefore, the management protocol required for this product is symptomatic and supportive treatment. Any care provided will focus on addressing any clinical changes that may manifest and maintaining vital bodily functions under medical supervision. The requirement to seek urgent medical help applies to any suspected overdose, regardless of the clinical signs present.

Therapeutic Uses of Mucothiol

What Mucothiol Treats: Main Uses and Benefits

Mucothiol is commonly used as a supportive medication specifically within therapeutic areas characterized by the production of abnormally thick and tenacious respiratory mucus (phlegm). Its primary role is to provide symptomatic relief and support efforts toward clearance when secretions may be difficult to manage. This therapeutic class is used for managing chronic respiratory diseases.


Easing Airway Symptom Burden

This medication is considered relevant in clinical settings where symptoms are driven by the physical viscosity of mucus, such as in cases of acute bronchitis or during exacerbations of chronic respiratory disease. The drug may be applied as an adjunctive treatment during acute, symptom-driven episodes, including pneumonia or complicated bronchitis, where the inability to clear heavy mucus complicates recovery. Mucothiol helps address the symptom cluster of strained, ineffective cough and difficulty in expectorating secretions, contributing to improved day-to-day comfort. It is commonly used across conditions presenting with acute episodes and for the long-term, supportive management of conditions like Chronic Bronchitis and COPD.


Quick Fact: Relief for Viscous Phlegm

Mucothiol is relevant for supporting relief for symptoms related to impaired secretion clearance and the high physical viscosity of phlegm, which interferes with daily functioning and contributes to temporary functional strain.

Eligibility and Restrictions for Use

Who Must Not Use Mucothiol (Contraindications)

The official regulatory labeling for Mucothiol defines specific populations for whom use is strictly prohibited. This includes any individual with a known hypersensitivity to the active substance, Carbocisteine, or any of the product’s excipients. Use is also an absolute contraindication in patients with an active peptic ulcer (gastric or duodenal) to avoid risk of exacerbation.

Age-Based Exclusion and Conditional Use

Mucothiol is contraindicated in children less than two years of age. Eligibility is granted to children over two years old, adolescents, and adults without any other contraindications. However, regulatory documents advise that use in the elderly is recommended with caution.

Special Population Restrictions

Use of Mucothiol is conditional for certain patient groups. Individuals with a history of gastroduodenal ulcers or pre-existing asthma/bronchospasm are eligible but must use the medicine with specific caution. Furthermore, for pregnant and breastfeeding individuals, the medicine is officially not recommended due to limited safety data documented in the labels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes drug and substance interactions for Mucothiol (carbocisteine) based exclusively on official government regulatory documents.


The primary concern in the official interaction profile involves pharmacodynamic conflicts and an additive risk for gastrointestinal (GI) complications.

Contraindicated Combination

Mucothiol is strictly contraindicated in patients with active peptic ulceration due to the risk of disrupting the gastric mucosal barrier, which may increase the potential for GI bleeding.

Pharmacodynamic Interaction Restrictions

Substance Category Interaction Statement Rationale in Labeling
Antitussives (Cough Suppressants) Use not recommended. May lead to accumulation of bronchial secretions by hindering the necessary cough reflex.
Secretions-Drying Agents (e.g., Atropinics) Use not recommended. May counteract the fluidizing, mucolytic effect of Mucothiol on secretions.

Use-with-Caution Combinations

Caution is advised when Mucothiol is co-administered with medicines known to increase the risk of gastrointestinal bleeding, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids, or antiplatelet agents. This precaution is heightened for elderly patients or those with a history of gastroduodenal ulcers.

Pharmacokinetic Interactions

Official regulatory documents generally state that there are no known clinically significant pharmacokinetic interactions involving major drug metabolizing enzymes (e.g., CYP) or drug transporters that require dosage adjustment of Mucothiol or the co-administered drug.

Mechanism of Action

Targeted Chemical Depolymerization of Mucus Structure

The primary mechanism involves the active metabolic component, the sulfhydryl ( -SH) group, directly engaging in a chemical reduction process within the respiratory tract. This -SH group targets and cleaves the intermolecular disulfide bonds (S-S) that rigidly cross-link the large mucin macromolecules ( MUC5AC and MUC5B), which define the viscosity of respiratory secretions. The resulting mucin depolymerization dramatically reduces the viscosity and elasticity of the secretions. This fluidification enhances the efficiency of the mucociliary apparatus, promoting the upward transport of secretions.


Prodrug Function and Redox Balance Modulation

Dacisteine functions as a prodrug, releasing L-cysteine, which is a rate-limiting substrate crucial for the synthesis of the body's major endogenous antioxidant, Glutathione (GSH). By providing the L-cysteine precursor, the drug supports the synthesis of GSH, thereby assisting the cellular redox system in neutralizing Reactive Oxygen Species (ROS). This modulation of the cellular redox state influences pathways related to inflammatory signaling (e.g., NF-kappa B), which are implicated in the regulation of mucus secretion.

Dosage and Administration Information

How to Use Mucothiol

Mucothiol, which contains the active ingredient Dacisteine, is intended for use exclusively via the oral route. This is consistent with its forms: the oral solution (syrup), film-coated tablets, and oral powder (sachet form). The overall protocol is structured to address both acute and long-term supportive needs.


Administration Scope Usage Principle
Route of Administration Oral (Exclusive pathway).
Dosing Schedule Determined by clinical presentation.
Frequency Pattern Typically administered in divided doses throughout the day to sustain systemic activity.
Use Context / Duration Utilized for both short-term courses during acute exacerbations and for long-term, continuous maintenance care.

Form-specific administration requires adherence to preparation rules. If using the oral powder, the contents must be fully dissolved in water or other non-alcoholic liquid immediately prior to ingestion. Conversely, the film-coated tablets must be swallowed whole without crushing or breaking to preserve the formulation's release characteristics and ensure proper delivery.

There are no universal instructions regarding administration timing relative to meals or missed-dose protocols in general product descriptions. These procedural steps ensure the Dacisteine is delivered into the systemic circulation, establishing a standardized usage protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Mucothiol

Evidence for Use in Chronic Bronchitis and COPD Management

Research has explored the long-term use of Mucothiol (Dacisteine) and related medicines in populations with Chronic Bronchitis and COPD. Studies focused on adults using Randomized Controlled Trials (RCTs) and meta-analyses that examined outcomes compared to an inactive substance (placebo). Researchers monitored the frequency of acute disease flare-ups (exacerbations), patient-reported quality of life (QoL), and lung function markers over extended periods, typically up to two or three years. Findings described patterns related to exacerbation rates and QoL scores. However, the evidence base is often reliant on data collected for the structurally related drug N-acetylcysteine (NAC).

Evidence for Use During Acute Respiratory Exacerbations

Mucothiol was studied for its use as an adjunctive treatment during acute episodes where symptoms suddenly become more noticeable. These were short-term RCTs that examined temporary imbalance in patients experiencing an acute worsening of their condition. Outcomes measured included physical discomfort, the rate of symptom resolution, and changes in objective lung function markers. Studies reported patterns observed in the measured outcomes related to symptom evolution. Due to the acute nature, follow-up durations were limited, typically lasting only a few days or weeks, meaning long-term effects are not fully established regarding recurrence.

Special Populations and Research Uncertainties

The main research overwhelmingly focuses on adults with established respiratory diagnoses. Data for certain groups remain insufficient, with limited information to characterize outcomes in pediatric populations (children) or those with specific co-existing medical conditions. The overall research is generally classified as providing a Moderate level of evidence. Key limitations include heterogeneity (variability) in reported results and the high reliance on data from the structurally similar medicine, N-acetylcysteine. Comparative evidence is lacking to definitively distinguish outcomes between the different formulations of this mucolytic class.

Key Studies & References

  1. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses
  2. Mucolytic Medications - StatPearls [Internet] (for general class mechanism and clinical context)
  3. DACISTEINE - Global Substance Registration System (GSRS) / PubChem (for chemical identity and structure class)

Frequently Asked Questions (FAQ)

Common questions about Mucothiol (FAQ)


Q: Is Mucothiol available without a prescription?

Mucothiol's regulatory classification, which determines if it is prescription-only (POM) or over-the-counter (OTC), can vary by country. While it is often classified as a prescription medicine in many regions, some health authorities may allow specific, lower-strength formulations or pack sizes to be designated for non-prescription availability.


Q: How does Mucothiol differ from other similar-sounding medicines?

Mucothiol is differentiated by its specific active ingredient, Dacisteine (N,S-Diacetyl-L-cysteine). This chemical structure sets it apart from other medicines in the same class, such as N-acetylcysteine or Carbocisteine. Official documents classify the medicine based on this unique composition.


Q: Can Mucothiol be used for purposes other than what is listed in the main description?

The official regulatory documents define the approved uses for Mucothiol based on the evidence reviewed by health authorities. Any discussion of unapproved uses, often referred to as 'off-label' use, is outside the scope of the medicine's official labeling, which establishes its known safety and effectiveness profile.


Q: How long does it typically take to notice the effects of Mucothiol?

Based on official pharmacokinetic data, the active substance typically reaches its highest concentration in the bloodstream within approximately one to two hours after the medicine is taken by mouth. The time to reach this maximum concentration provides a reference point for when the substance is most active in the body.


Q: Is it necessary to finish the entire supply of Mucothiol even if I feel better?

Official information describes that Mucothiol is utilized for both short-term treatment during acute periods and long-term continuous maintenance care. The prescribed duration of use is determined by the patient's specific health condition. Patients may wish to consult with a healthcare professional regarding the appropriate duration of use for their condition.


Q: Is Mucothiol considered safe for long-term use?

Official safety data and regulatory precautions address the use of Mucothiol over extended periods. The official labeling describes the known safety profile and monitoring requirements that are necessary when the medicine is administered for continuous, long-term management.


Q: Are there any specific activities to avoid while taking Mucothiol?

The official labeling does not commonly report specific activities that must be avoided. However, regulatory information advises that patients who experience reported side effects, such as dizziness, should be aware of the potential impact on activities that require attention.


Q: Can Mucothiol affect my ability to drive or operate machinery?

Official labeling generally does not include specific warnings suggesting that Mucothiol directly impairs driving ability. Patients should observe their personal response to the medicine, and the potential for operating vehicles or heavy equipment should be considered in light of any reported central nervous system side effects.


Q: Is Mucothiol known to interact with herbal supplements or vitamins?

Official regulatory documents focus primarily on established interactions with other prescribed medicines. Since non-standardized substances like herbal supplements are generally not part of the clinical trial process, specific interaction data with these products is often unavailable in the official labeling.


Q: What is the current regulatory status of Mucothiol in major health organizations?

Mucothiol (Dacisteine) has received Marketing Authorization from key governmental health organizations, such as the European Medicines Agency (EMA), and is listed in various national drug compendia. This confirms that its use is officially authorized and regulated in those territories.


Q: Are there any specific dietary restrictions recommended while taking Mucothiol?

Official regulatory labeling generally does not mandate specific dietary restrictions or changes while taking Mucothiol. The labeling may contain non-directive information on administration timing relative to meals based on studies of its uptake, but no specific foods are officially listed as contraindications.


Q: Does Mucothiol have any known interactions with alcohol?

Official regulatory documents typically advise caution regarding the use of Mucothiol with alcohol. This precaution is often based on the potential for alcohol to increase the risk or severity of certain side effects, particularly those related to the gastrointestinal system.


Q: Does Mucothiol have a strong taste or smell?

The oral solution and syrup formulations often include specific excipients (non-active ingredients) like flavorings and sweeteners to improve palatability. Similarly, film-coated tablets are designed with coatings to mask the natural taste of the active ingredient, Dacisteine.


Q: What kind of specialist typically prescribes Mucothiol?

Given its official use in chronic respiratory conditions, Mucothiol is commonly prescribed or managed by healthcare professionals specializing in this area, such as general practitioners, family doctors, or pulmonologists (lung specialists).


Q: Is it normal to feel a change in appetite after starting Mucothiol?

Changes in appetite are generally not listed as a common side effect in official regulatory documents. However, since gastrointestinal effects are sometimes reported, such as nausea, this may be a factor in a perceived change in appetite.


Q: Can Mucothiol cause changes in sleep patterns?

Official regulatory documents do not commonly list changes in sleep patterns, such as insomnia or excessive drowsiness, as common side effects. Potential effects on the nervous system are categorized and described by frequency in the official safety profile.


Q: Are there any known interactions between Mucothiol and caffeine?

Official regulatory labeling does not typically cite specific, clinically significant interactions between Mucothiol and caffeine. The overall interaction profile focuses on medicines and substances that affect the body in ways relevant to its mucolytic action.


Q: Does Mucothiol affect blood pressure or heart rate?

Effects on blood pressure or heart rate are generally not reported as common adverse reactions in official safety profiles. Any cardiovascular changes would be listed under the less frequent tiers of the official System-Organ-Class for Cardiac or Vascular Disorders.


Q: Is Mucothiol available as a generic medicine?

The status of Mucothiol as a generic medicine is tracked by regulatory databases, which monitor the patent and exclusivity status of its active substance, Dacisteine. The availability of generic equivalents depends on whether they have received official marketing authorization.


Q: What information is legally required to be on the Mucothiol packaging?

Official regulations mandate that product packaging includes essential information, such as the drug name, the active ingredient (Dacisteine), strength, pharmaceutical form, quantity, excipients (non-active ingredients), manufacturer details, dosage information, storage instructions, and all necessary warnings.


Q: Can Mucothiol affect the results of lab tests?

Official labeling may document the potential for the active substance in Mucothiol, or its metabolites, to interfere with certain common laboratory assays (tests). Any such interference requiring precaution is specified in the regulatory warnings section.


Q: Why do some people report feeling tired when taking Mucothiol?

Fatigue or drowsiness may be reported as a possible side effect and is officially categorized within the System-Organ-Class for Nervous System Disorders. The official safety documentation defines the reported frequency of this effect based on clinical data.


Q: What happens if I accidentally take more Mucothiol than prescribed?

Official regulatory documents include a section detailing the expected effects of an overdose, which typically involve an increase in reported side effects. This section also outlines the general procedures for managing accidental or intentional excessive use.


Q: Is Mucothiol considered a controlled substance?

Mucothiol (Dacisteine), which is classified as a mucolytic agent, is generally not classified as a controlled substance under national or international drug scheduling systems. It is not considered to have a recognized potential for abuse or dependence.


Q: Does Mucothiol have a potential for dependence or withdrawal effects?

Official regulatory documents generally do not list a potential for dependence or withdrawal effects for Mucothiol. It is not classified as a scheduled substance with known abuse liability, and its warnings focus on other potential risks.


Q: What types of food are known to interfere with Mucothiol's absorption?

Official pharmacokinetic data or interactions sections generally specify if food significantly impacts the absorption of Mucothiol. The labeling may contain non-directive information on administration timing relative to meals based on studies of its uptake.


Q: Are there any warnings about sunlight exposure while taking Mucothiol?

Official regulatory documents are checked for warnings regarding photosensitivity, which is an increased sensitivity to sunlight. Such warnings are included in the labeling if exposure has led to reported adverse skin reactions in clinical studies.


Q: How long after stopping Mucothiol does it stay in the body?

The duration Mucothiol remains in the body is characterized by its elimination half-life (T1/2), which is officially reported in pharmacokinetic studies. The active substance and its related metabolites are primarily cleared from the body through the kidneys.


Q: Can Mucothiol be used alongside inhalation therapies?

Official regulatory documents generally address the use of Mucothiol alongside other common respiratory treatments, including inhalation therapies. The labeling specifies any necessary cautions or warnings regarding the combined use of these treatments.

How should Mucothiol be stored and disposed of?

How to Store and Dispose of Mucothiol?


The official storage and disposal instructions for Mucothiol (Carbocisteine oral solution) are governed by regulatory labeling to ensure product quality and safety.

Storage Requirements

Condition Type Requirement
Temperature Limit Do not store above 25 C.
Protection Protect from direct heat and light.
Child Safety Must be kept out of the reach of children.

Stability and Disposal

The unopened product typically has a shelf life of 30 months. Once the bottle is opened, the solution must be used within 6 months. Any unused or expired medicine must be disposed of in accordance with local regulatory requirements. Medicines should not be discarded via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucothiol found in:

A-Z Index: